# Spring 2013 Genomics Exam #2 Sequence Variations and Microarrays

There is no time limit on this test, though I don't want you to spend too much time on it. I have tried to design an exam that will take less time than exams in the past. You do not need to read any additional papers other than the ones I send to you. There are **5** pages, including this cover sheet, for this test. You are <u>not allowed discuss the test with anyone</u> until all exams are turned in no later than 10:30 am on Wednesday March 27. **ELECTRONIC COPIES OF YOUR EXAM ANSWERS ARE DUE BY 10:30 am ON WEDNESDAY MARCH 27**. You may use a calculator, a ruler, your notes, the book, and the internet. You may take this exam in as many blocks of time as you want. Submit your electronic version before 10:30 am (eastern time zone).

The **answers to the questions must be typed in a Word file and emailed to me as an attachment**. Be sure to backup your test answers just in case (I suggest a thumb drive or other removable device). You will need to capture screen images as a part of your answers which you may do without seeking permission since your test answers will not be in the public domain. Remember to explain your thoughts in your own words and use screen shots to support your answers. Screen shots without *your* words are worth very few points. Support your answers with data using screen shots liberally (no permission required since your exam is a private document).

# DO NOT READ or DOWNLOAD ANY PAPERS FOR THIS EXAM. RELY ON YOUR EXPERIENCE, AND YOUR SKILLS.

#### -3 pts if you do not follow this direction.

**Please do not write or type your name on any page other than this cover page.** Staple all your pages (INCLUDING THE TEST PAGES) together when finished with the exam.

Name (please type):

Write out the full pledge and sign (electronic signature is ideal):

How long did this exam take you to complete?

# 20 points

1) To understand what these investigators did, watch <u>this video</u>. Do NOT look up the paper or the abstract. It is important that you ONLY use the data in this exam to answer the questions below. If the video does not load properly via Word, copy the URL and paste it into your browser. It should work that way.



burrows. (a) Sampling of burrows at eight sites in the southeastern United States from across the range of *P. polionotus* (grey area). Average percentage of soil silt at each sampling site is provided. (b) Diagram of a typical P. polionotus burrow showing the measures for entrance-tunnel length, total length and burrow depth, as well as a typical escape tunnel. (c) Variation in total burrow length among sites (mean  $\pm$  range), which are ordered by increasing percentage of silt (left to right). (d) Correlation between silt composition of soil and burrow depth (asterisk indicates Spearman correlation). Each point represents a burrow, and shapes represent the eight different sampling sites. The number of burrows measured at each site is shown in

Figure 1. Natural variation in *P. polionotus* 

parentheses.

Figure 2. Burrow variation across generations. (a) Burrow dimensions of *P. maniculatus* (Man; yellow), *P. polionotus* (Pol; blue),  $F_1$  hybrids (dark green) and progeny resulting from  $F_1 X P$ . *maniculatus* backcross (BC; light green). Pie charts depict average genome composition in each generation. Distributions of entrance-tunnel length in the parental species,  $F_1$  hybrids and BC animals are shown (average of three trials for each mouse tested). Boxes represent interquartile ranges (median  $\pm$  s.d.). Significant t-tests, \*P =  $5 \times 10^{-3}$ , \*\*P =  $2 \times 10^{-4}$ . (b) The frequency of escape-tunnel construction is shown for the same individuals. Error bars represent mean  $\pm$  standard error of the mean (s.e.m.) Sample sizes are listed in parentheses below.



Figure 3. Genomic analysis of burrow variation.

(a) Linkage groups (LGs) 1, 2 and 20 with log-transformed average entrance-tunnel length (black line). Linkage group 5 with escape-tunnel presence (red line). Dotted line represents log odds



ratio (lod) significance threshold (genome-wide  $\alpha = .05$ , lod ~ 3.0). 1.5lod confidence intervals and scale in centimorgans (cM) are shown in light blue. Dashes indicated genetic markers, and black arrows indicate markers used to define each peak (used in b). (b) Phenotypic effect of individual and

combined genotypes (linkage groups 1, 2 and 20) on entrance-tunnel length in 272 BC mice.

(c) Proportion of BC animals that construct escape tunnels for each of the two genotypes. All error bars represent mean  $\pm$  s.e.m. Blue and yellow lines represent average phenotype of the

parents (pure species) used to found the cross. Genotypes are either homozygous *P. maniculatus* (MM) or heterozygous *P. maniculatus/polionotus* (MP).

# Questions:

# 10 pts

a) Please write an abstract limited to 200 words maximum. Your goal is to summarize the research in Figures 1 - 3.

Various answers. Needed to discuss 3 QTLs for tunnel length and 1QTL for escape tunnel. Cannot distinguish if one gene or haplotypes of alleles at each QTL.

Escape tunnel locus looks dominant except the clear but are polygenic for sure. There must be another locus for escape tunnel too, but they did not find it.

# 5 pts.

b) Choose a model genome that is closely related to the species in this study. Use this model genome to design a method to identify the alleles responsible for the behaviors in the original species once the two genomes from these species in the paper are fully sequenced.

Mouse and look for syntenic regions and identify locus near markers shown in Figure 3A. (see right)

is musculus	(laborator	y mo	use) Build 38.1	(Current)			<b>BLAST laboratory mouse sequence</b>
romosome:	[1]2345	5789	0 10 11 12 13 14 1	5 16 17 18 19 X Y MT			
aster Map: M	GI Genetic			Summary of Ma	ps		Maps & Option
gion Displayed	: 65.00-75.00	) cM		_			
es_seq⊉X HI	/HRC-RH	HGIX 1	Symbol	Type	Lit	<u>iks</u>	Description
En1	+	L	1 giq1	GENE	MGIGen	TINCTO	ngiyeende QTL 1
	BA959943 BU022885	17	E550020D12Rik	GENE	MGIGen	Unists	Riken CDNA E550020D12 gene
	÷	Ŧ ŀ	Gm6652	GENE	MGIGen		predicted gene 6652
	01050360	₹ \	Rgs16	GENE	MGIGen	UniSTS	regulator of G-protein signaling 16
Actes	-	Ť Γ	D1Mit34	GENE	MGIGen	UniSTS	DNA segment, Chr 1, Massachusetts Inst
Meats Coort	RH126248	‡  r	Qsox1	GENE	MGIGen	1	quiescin Q6 sulfhydryl oxidase 1
C455 Zp3r C4be		1	D1Mit451	SEQUENCE TAGGED SITE	MGI	UniSTS	DNA Segment, Chr 1, Massachusetts Ins
All and and a	A1064948	±Ł	Vmbic1	GENE	MGIGen		ventral midbrain iron content 1
Rassf5 Hoke Aver 1b	D1M14393 R1488971	Ŀ	Rasal2	GENE	MGIGen	1	RAS protein activator like 2
Chae Coto2	+	$\mathbb{I}$	1700057K13Rik	GENE	MGIGen	2	RIKEN cDNA 1700057K13 gene
Mdv4 Nicel	687253	ŧη/	D1Mit202	SEQUENCE TAGGED SITE	MGI	UniSTS	DNA segment, Chr 1, Massachusetts Inst
Gox13 At#264	R1323748 88285655 R1195242	1	Stia1	GENE	MGIGen	2	serum transfer induced arthritis 1
Chi311	#RI195242 #95547 RH126628	ħ	Gm7430	GENE	MGIGen		predicted gene 7430
Hupe Adjport	H17897 H1986869 AN550201	1	D1Pgn7	SEQUENCE TAGGED SITE	MGI	UniSTS	DNA segment, Chr 1, Paigen 7
Elfo	897399 58162516 81858289	<u></u> =//	4930523C07Rik	GENE	MGIGen		RIKEN cDNA 4930523C07 gene
Cornals Nr5a2	RU023994	割/(	Mrps14	GENE	MGIGen		mitochondrial ribosomal protein S14
Pterc	#HRs21c6 #R1666441 X16642	ΞŴ	D1Dcr15	SEQUENCE TAGGED SITE	MGI	UniSTS	DNA Segment, Chr 1, Derry C. Roopen
Lhx9 Cr61	-RA959590 R1131919	ŦŴ	Gm2378	MARKER	MGI		predicted gene 2378
- Aero Ofh	RH118245 RH268766 R1448359	ŧn\(	D1Mit505	GENE	MGIGen	UniSTS	DNA Segment, Chr 1 Massachusetts Inst
	RI040715 RI055640 RM822012	₹ W.	D1Mit106	SEQUENCE TAGGED SITE	MGI	UniSTS	DNA segment, Chr 1, Massachusetts Inst
		11	Mettl13	GENE	MGIGen		methyltransferase like 13
-01ev2	RH127036	± %	Emo1	GENE	MGIGen		flavin containing monooxygenase 1
Res2 Res2	R1646342	±.11	Fmo4	GENE	MGIGen		flavin containing monooxygenase 4
	+	Ξ \()	Mettl11b	GENE	MGIGen		methyltransferase like 11B
	÷	1. N	4930455E23Rik	GENE	MGIGen		RIKEN CDNA 4930455E23 gene
		1 \\"	Gm16550	MARKER	MGI	¢.	nmdiated gaps 16550
	C77892	‡ //,	D1Mi+520.2	SEQUENCE TACCED SITE	MCI	UNCTO	DNA segment Chr.1 Messachusetts Inst
	RH126465	₽l,	Groad	GENE	MCICon	011313	alvaaneetain A 22 (tennemamherana)
P4c Prof	B0203640 R1458156	₹ /,	Gpa55 Ema0	GENE	MCIC		fouin containing manageurgen
Ionaloby Rnf2		ŧ	F11109	GENE	iviGI Gen		navin containing monooxygenase 9

#### 5 pts.

c) I want you to evaluate the model species you chose. How close to the target species is your model species? Use genome-scale evidence to support your answer, not individual genes. *Mus musculus* has 19 autosomes but the species in the paper have *P. maniculatus* has 23 autosomes which means they cannot have completely syntenic genomes. Therefore mapping QTLs between these two species may be difficult.

http://www.ncbi.nlm.nih.gov/genome/?term=txid10042[Organism:exp]

#### 20 points

2) Number two contains a series of unrelated but interesting tidbits that I'd like you to ponder. Don't look for these papers or their abstracts. Use sequence databases to answer these questions. a) "Strikingly, we find that human Leptin can rescue the *upd2* mutant phenotypes, suggesting that fly Upd2 is the functional ortholog of Leptin." How similar are these two proteins? Support your answer with data. Limit your answer to a maximum of 2 sentences plus screen shot(s). Fly: NP\_573277

#### Human leptin: AAH69452

Normal BLAST2 alignment gave me no similarity.

Edit and Resub	mit Save Search Strategies	► Formatting options	⊳ <u>Download</u>		You Tibe How to read this page	Blast report description				
Blast 2 sequences										
ref NP_573277  (370 letters)										
Query Descripti Molecule ty Query Leng	(D gil2813610711refiNP 5 nunpaired 2 [Drosophila m melanogaster] > gil2304 >gil383278106(gblAFG e amino add 370	73277.2  elanogaster) >gi 2725(5 91292 gb ADD31625.1 99700.1  RT12650p1 [0	66158/gb/AAF48815.2/ unpaired 2 RT06576p1 [Drosophila melanoga rosophila melanogaster]	[Drosophila Subject ID ster] Molecule type Subject Length Program	g 46854679 gb AAH69452.1  leptin precursor [Homo sapiens] >g 730218 sp P41159.1 LEP_HUMAN F Althame: Fill=Obese protein: AttName: Full=Obesity factor; Flags: Precur >g 623323 gb AA460470.1  ob [Homo sapiens] >g 1226244 gb AA55 [Homo sapiens] >g A049501[db]Ah [His31] lo protein [Homo sapiens] >g 14695479]  gb AA4561413 gb Ah(169527.1  Leptin [Homo sapiens] >g 4685479 gb AA46647111 gb Ah(169527.1  Leptin [Homo sapiens] >g 4685479 gb AA46647111 gb Ah(169527.1  Leptin [Homo sapiens] >g 468546740]gb AA46647111 gb Ah(169527.1  Leptin [Homo sapiens] >g 468546740]gb AA46647111 gb Ah(169527.1  Leptin [Homo sapiens] >g 468546740]gb AA4664711 gb Ah(169527.1  Leptin [Homo sapiens] >g 468546740]gb AA4664711 gb Ah(169527.1  Leptin [Homo sapiens] >g 4685478470]gb Ah(169427.1  Leptin [Homo Sapiens] >g 4685478470] (basis) [Homo sapiens] >g 208968561 db] BAG74119.1  leptin [synthe amino add 167 BLASTP 2.2.28+ ▶ <u>Citation</u>	tecName: Full=Leptin; 507 400.1  obese protein AA460830.1  Leptin b[6L24315.1] leptin 1  leptin (obesity n (obesity homolog, tic construct]				
No signific	int similarity found. For re	asons why, <u>click here</u>								
Other reports	⊳ Search Summary									

#### CLUSTALW alignment:

CLUSTAL 2.1 multiple sequence alignment

Human_Leptin Fly_Upd2	MILSVVMPFTKARHLRDQVALDYAYDEDNSGRSSSSSSSSSSSGGDILPAFDVNPYRGLA	60
Human_Leptin Fly_Upd2		4 120
Human_Leptin Fly_Upd2	TLCGFLWLWPYLFYVQAVFIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTG NPCGGTYTPDESLSDSSASQGRVIKRKHLENLRNITMSEYQDITHRATLEYGNLQHWQRE . ** : : .:. :*:.* : ::. :**:* ::. ::	59 180
Human_Leptin Fly_Upd2	LDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRN	101 240
Human_Leptin Fly_Upd2	ENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASG VSARYMLCEIELTINASYPNSNGAKLSRVSRQAMEERLNFHTPANGSMEADQRDLKVSKE . * :* : :: * :.* *:. *:.*	139 300
Human_Leptin Fly_Upd2		167 360
Human_Leptin Fly Upd2	SGSDGGSNES 370	

What is really interesting is that these two proteins have very little sequence conservation and yet functionally, the human leptin protein can functionally rescue udp2-/- flies. There are some conserved amino acids so perhaps this degree of conservation is sufficient to replace the missing Udp2 protein so similarity must be qualified by function or primary protein structure.

b) Find the SNP responsible for "immigration delay disease." You have to show me the wt DNA sequence to get full credit. You also have to explain why this SNP causes a change in phenotype. Autosomal dominant allele.

#### From OMIM: .0001 ADERMATOGLYPHIA SMARCAD1, IVS1, G-T, +1

In affected members of a 4-generation Swiss kindred with adermatoglyphia (136000), originally studied by Burger et al. (2011), **Nousbeck et al. (2011) identified heterozygosity for a G-T transversion in intron 1 of the SMARCAD1 gene (378+1G-T), predicted to abolish the donor splice site adjacent to the 3-prime end of the first unique exon of the skin-specific short SMARCAD1 isoform.** The mutation segregated with disease in the family and was not found in 100 Swiss controls or in 100 Jewish controls. Transfection into HeLa cells and into primary human fibroblasts followed by RT-PCR revealed that the mutant yields 2 aberrant splice variants, both of which were only marginally detectable compared to wildtype. Experiments with cycloheximide showed that the aberrantly spliced variants of the

SMARCAD1 short isoform undergo degradation.

 ${\tt CTCTCAGCTGGGATCGCGCCGCGTCAACTTCCGGGCGGATGCCCGCCAGCACGGCCTCCGCCGCTCCCCT}$ CACGGTAGCACAGGGAGCTTCTCTTTGTGGGCGGGCGCGAGGCCCGCTAGGGGGGTTATACTGGGGAACGT GCCTGCGCGTGCTTGGATAGTTCATTTAAAGCCCCCATCCCTGCAAGGTGGTGCTTTCTACCAATATGAA TCTTTTCAACCTGGACCGTTTTCGCTTTGAGAAAAGGAATAAGATTGAGGAAGCGCCCGAAGCAACCCCT CAACCTTCCCAGCCTGGCCCTTCTTCACCAATTTCTCTTAGTGCTGAAGAGGAGAATGCTGAAGGGGAAG TTAGCAGGGCAAACACTCCTGATTCAGATATAACTGAAAAAACAGAAGATTCTAGTGTTCCAGAAACTCC AGATAATGAAAGAAAAGCAAGTATATCATATTTCAAAAAATCAAAGAGGAATACAGTATATTGATTTGTCT TCTGATAGTGAAGATGTCGTTTCCCCCAAATTGCTCCAATACAGTTCAAGAGAAAACATTCAACAAAGATA CAGTGATTATAGTTTCTGAGCCATCTGAAGATGAAGAGTCCCAAGGCCTTCCTACCATGGCACGTAGAAA TGATGATATTTCAGAACTGGAAGACCTTTCGGAATTGGAAGACCTTAAAGATGCTAAACTTCAGACTTTG AAGGAACTTTTTTCCACAAAGAAGTGACAATGATTTACTTAAGTTGAATCAACAAGCACTATGGATG GAGCAATTGCTGCTGCCTGCTGATGTTTGGTGATGCAGGTGGTGGGCCCAGGAAAAGAAAATTATCTTC TTCTTCAGAGCCATATGAGGAAGATGAATTTAATGATGATCAATCTATAAAAAAGACAAGACTGGATCAT GGAGAGGAATCAAATGAGTCTGCAGAATCTAGCAGTAATTGGGAAAAGCAGGAAAGTATTGTACTGAAAT TGCAAAAGGAATTTCCCAATTTTGATAAACAGGAACTTAGAGAAGTACTCAAGGAACATGAATGGATGTA  ${\tt CACAGAAGCTTTAGAATCTCTAAAAGTGTTTGCAGAAGACCAAGATATGCAATATGTATCACAAAGTGAG}$ GTTCCAAATGGAAAAGAAGTTTCTTCAAGAAGTCAAAATTACCCTAAAAATGCAACTAAAACAAAACTAA GAGAGTTGTTGAAGACTCTGAATATGATTCAGGTTCTGATGTCGGTAGTTCACTAGATGAGGACTATAGT GTGAACTTACTTTGATTCCTCAGTGTTCTCAGAAAAAGGCTCAGAAGATAACAGAACTCCGGCCCTTTAA TAGTTGGGAGGCTCTGTTCACAAAGATGTCCAAAACTAATGGCTTATCAGAAGATTTGATATGGCACTGT  ${\tt CTTAATGGCATTTTGGCAGATGAAATGGGCCTAGGAAAAACTATTCAAGCCATTGCATTTCTGGCATACC}$ TCTATCAGGAGGGTAATAATGGTCCTCATTTGATCGTTGTTCCAGCTTCAACTATAGATAACTGGTTAAG GGAAGTTAATTTATGGTGCCCTACTTTGAAGGTCCTCTGTTACTATGGTTCTCAAGAAGAACGTAAACAA **ATTAGATTTAACATTCATAGTAGATATGAAGATTACAATGTAATTGTGACCACATATAACTGTGCGATCA** GCAGTTCTGATGACCGTAGTCTGTTTCGACGGCTGAAACTTAATTACGCAATTTTTGATGAGGGCCATAT  ${\tt GCTGAAGAATATGGGCTCCATTCGCTACCAGCACCTTATGACAATTAATGCAAATAACCGTTTGCTGCTC}$ ACAGGCACCTGTACAGAACAATCTGTTAGAACTCATGTCGCTGTTGAATTTTGTTATGCCACACATGT

<sup>&</sup>gt;gi|363807327|ref|NM\_001128429.2| Homo sapiens SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 (SMARCAD1), transcript variant 1, mRNA

TTAGTAGTAGCACCAGTGAAATACGAAGAATGTTTTCCTCTAAGACAAAATCAGCAGATGAGCAAAGCAT ATATGAAAAGGAGAGAATAGCACATGCAAAACAAATTATAAAGCCATTTATTCTCAGAAGAGTAAAAGAA GAGGTTCTCAAGCAGTTACCCCCCAAGAAAGATCGAATTGAGTTGTGTGCAATGTCGGAGAAGCAGGAGC AATGTGCAATGTCATGATGCAGTTGAGGAAAATGGCCAATCATCCTTTATTACATCGCCAATATTACACA GCTGAAAAAACTCAAGGAAATGTCTCAGCTTATGCTAAAGGAACCTACACATTGTGAGGCTAACCCTGACC TGATCTTTGAAGATATGGAAGTTATGACAGACTTCGAACTACATGTACTTTGTAAACAGTACCGACACAT TAATAACTTTCAGTTAGACATGGACTTGATTTTAGATTCTGGAAAATTTCGAGTTTTAGGATGCATCTTG TCTGAATTGAAACAGAAGGGTGATAGAGTTGTGTTATTTAGCCAATTTACCATGATGCTGGATATCTTAG AGGTTCTATTAAAACATCATCAGCATAGGTACCTCAGATTAGATGGAAAGACTCAGATTTCTGAAAGGAT TCATCTAATTGATGAGTTTAATACCGATATGGATATCTTTGTGTTTCTGCTATCAACAAAAGCTGGTGGA TTAGGAATAAATCTGACTTCAGCAAATGTTGTTATACTTCACGATATTGACTGTAATCCTTATAATGACA AACAAGCAGAAGATAGATGCCATAGAGTAGGCCAGACTAAAGAAGTACTAGTTATAAAACTAATAAGCCA AGGGACGATTGAAGAATCCATGCTAAAAATTAACCAACAGAAATTGAAACTAGAACAGGATATGACTACA GTAGATGAAGGTGATGAAGGGAGTATGCCAGCAGATATAGCCACATTACTAAAAAACATCAATGGGCCTGT GAAATAAGAACTGTGAACTCTCAATTGATGAGGAAATATCAACTTGGTGCACTCAAGGACATTTACATTA TGATGACCATGGGGTTTATGAACATTTATAACTTTTTATAATTTCCATATTACATTTCTCATAGTATGGA CAACTTTTTGCCACTAACTGAATTCTCCAAAATACTCACACGTGAAATTTCAAAAAAAGAAGCCACAAATAT GTAGTTCTGAAGATGTTGAATAATCATTTTACAAAGCAGTTTTCTGAATGGGGATTAGTTGGTGATTGTT TATTGTCTTTCACTGGATAATGTGTGTGTAGATTTTTACATGTGCCTTATTTGACAATGCTTATGTCTTGTT ATTTTATTGCTATTTGAAGCAGATGTTCACCAATGTCAGCAAGAACTCAACCTGAATTTAAAGGTGGCAT AGTTGTTTTCCAGTGAATAGTAACTAAAGAAGCCCCTACCTTGCTCCATGGATTAATTCCTTCTGTTCAT TTTCCAACTGCACTAATTGTGCATATTACTCTGCCTAATCTTGTGCATGTTTTCATTGATTTCCCTCTCC TTTATTACTGCCACATCTCCATGCATCAGCAAAATGTTGGTGACATTTTTCTAGCCTGGCAGAACAGATT ACTTAAAGCTATTTCATTCAAAGCAGACTGAATGTGACTTCATCTAAAGGCAGCATTAGGTACTGCATG GAAATAGGTCATTAACTTGAAACTCTTATCAAAATATATTTTACCAGTTTCCAGAATTTCCAGTACAGGA **TTTTATTATACATCAGTTTCTTTGTATAACTTGTGAGTTCCATGTGTTTTGTTTTATTATGTAAATATC** ATTATAAATAAACTTATTATAAAATCAAAGATTTGTTAATTTTTGGAAATCATGCTTTTCAAAGCATCCT AACTTGCTAAGATGCTAGGTAGTACGACCCTCTGGATTTGGAAGGCAAATAAAACTCTTACAGTGATTAT TTAGATATTAAAGACTGAGAACTCACGGCTTAACCCCAGTCTTGATGGTATATTGAACAGACTGAATATA TTTTACCATTACAGGGCTAAAAGGAGTCTTCATGTGTTAATACTACCTCCTTGTACATCACTATACCCAA ATCAGTTATTCAAATTGTTAGGAATTTTACCTTTTAAAATCTCATAATGGATATCTCATGTTTTCTGTAT TAATGTATTTCAATGATAGGCTGTTTCTTTTTTTGTTGTTGTTGTTGTTGTTGTTATATCCATACTTTT **ATCTCTAATGAAATGTAGTTGGGTTCTTCCTGTAATGCGCTATTATGTCTTGGGCTTAATAAAAATATTT** GTGATCATAAAAAAAAAAAAAAAAA

c) On the next page is a figure taken from a paper published in 2012. Do not look for this paper, but instead, I want to see if you can assemble a reasonable hypothesis based on the data. The context was a massive study of early human evolution. The investigators sampled hundreds of Africans with a special emphasis



on tribes based in the southern half of Africa. They used a statistical measure (aPBS) which you don't need to understand. The aPBS measure was designed to identify regions of recent selection ( $\leq 100,000$  years ago) that may have distinguished modern *Homo sapiens* from other hominids. Investigate information about the named points in the figure and speculate what anatomical features were being selected for that lead to the modern human physique. I want you to focus on

no more than two general traits in your speculation and summarize your ideas in a maximum of 5 sentences. Be sure to use all the named points when formulating your answer.

#### Bone, skull and vision

#### 30 points (5 pts each)

3) These questions focus on breast cancer sub-types. Please do not look for the *Nature* paper or any commentaries on it (other than what we already covered in class – you can go back to those readings but I doubt they will prove insightful). **Look at the attached Figure4.pdf file.** ER = estrogen receptor. PR = progesterone receptor.

a) Summarize what you notice about PIK3CA in breast cancers. Support your answer with data. Limit your answer to no more than two sentences.

missense in almost half except basal-like

CNV amplified in basal for at least half

b) Which cancer type(s) look the most homogeneous and which one(s) look the most heterogeneous? What are the clinical implications of your interpretation? Support your answer with data. Limit your answer to no more than four sentences total.

Luminal A and B have many diverse mutations and CNVs

HER2-enriched looks intermediate with high degree of TP53 and fewer other mutaitons.

Basal-like looks the most homogeneous (TP53 and few others).

Clinical implications are the two luminals may not respond the same way to treatment while Basal-like might perform more uniformly.

c) Comment on the mutations per Mb for each breast cancer subtype. Support your answer with data. Limit your answer to no more than two sentences.

HER2-enriched has the highest mutation rate overall and more samples that exceed the indicated threshold at 50%. Basal-like is second with fewer extremely mutated samples followed by luminal B (and a few extremely mutated samples) with luminal A samples having the fewest mutations overall, though a few samples reach the 50% mark.

#### Look at **Figure5.pdf** for the remaining questions.

d) Summarize the significance of panel a. Support your answer with data. Limit your answer to no more than two sentences.

With the exception of BRCA2, ovarian and basal-like breast cancers have many similar genes differentially expressed (induced red and repressed blue). This might lead to common treatment for these two cancer types.

e) It might seem odd to have breast cancers on the Y-axis and breast cancer subtypes also on the X-axis. What can you conclude from just this portion of the data in panel b? NL = normal-like breast cancers. Support your answer with data. Limit your answer to no more than two sentences. You can see that basal-like breast cancers are the most similar to each other (lots of yellows) and the opposite of the two luminal cancer types (intense blues). HER2 and luminal B are the next most internally similar but luminal A is diverse even when compared to other luminal A samples (see inconsistent yellows)

f) What is the utility for comparing different breast cancer types against other non-breast cancers? Cite specific examples from panel b to illustrate our answer. Limit your answer to no more than two sentences.

Normal-like breast cancers are more like kidney cancer, basal is similar to lung and ovarian while liminal A is most like prostate cancer which is unexpected. This could lead to trying already approved drugs for one cancer on the other similar cancer.

### 30 points (5 pts each)

4) The final question is based on another paper but I don't want you to look for this one either. The educational goal is for you to demonstrate your ability to interpret the information I provide on this exam. You can look up genes or terms online, but please don't go looking for this paper, its abstract, or any commentaries on this paper.

#### ABSTRACT

After traumatic injury, peripheral nerves can spontaneously regenerate through highly sophisticated and dynamic processes that are regulated by multiple cellular elements and molecular factors. Despite evidence of morphological changes and of expression changes of a few regulatory genes, global knowledge of gene expression changes and related biological processes during peripheral nerve injury and regeneration is still lacking. Here we profile global mRNA expression changes in proximal nerve segments of adult rats after sciatic nerve transection. According to DNA microarray analysis, a huge number of genes was differentially expressed at different time points (0.5 h–14 d) post nerve transection, exhibiting multiple distinct temporal expression patterns. The expression changes of several genes were further validated by quantitative qPCR analysis. The gene ontology enrichment analysis was performed to decipher the biological processes involving the differentially expressed genes. Collectively, our results highlight the dynamic change of the important biological processes and the time-dependent expression of key regulatory genes after peripheral nerve injury. Hopefully, this study may provide a useful platform for deeply studying peripheral nerve injury and regeneration from a molecular-level perspective.

# Open the file **Question6A.pdf**

a) Produce a numbered list the cluster of genes from fastest (#1) to slowest (#last) to response to the transection. You may preface your list with no more than one sentence.

It was hard to determine the order, so I was pretty flexible in grading. I moved halfway down the list of genes and determined what time point was intense red. This gave me a fairly objective

way to determine order. The further to the right induction was at midway down the list of genes, the faster that response had happened. The slope of induction was determined by the number of early genes which not a good measure, but it would be easy to get fooled this way by the visual perception of rapid induction. You cannot use the middle column because that is always the same time point. However, you could use the middle column and ask how far down the list of genes are activated by the mid time point.

- 1. immune response & axon guidance & axon regeneration (4 days)
- 2. proliferation & apoptosis (1 day)
- 3. inflammation & migration (9 hr)
- 4. response to stimulus (4hr)
- 5. myelination (1 hr)

b) Can you find a gene that appears to return to its basal state at day 14? Explain your answer in no more than two sentences.

Many of the genes in the middle of pathways start repressed and return to repressed since their time has come and gone. See screenshot of several examples, though there are many more in several of the clusters.





Myelination



d) Design a research program that uses these data to develop a treatment to stimulate human nerve regeneration in the case of accidents. Support your answer with data. Limit your answer to no more than four sentences.

The inflammatory and immune responses may not be involved in regeneration, so I would focus my attention on the next three classes of genes: regeneration, proliferation and migration. I would look for compounds or physical stimuli that could induce these three gene clusters in hopes that I could stimulate nerve regeneration anytime they were damaged.

#### **Open the file Question6B.pdf from the same paper.** RT = reverse transcriptase.

e) Summarize the results from this figure. Support your answer with data. Limit your answer to no more than two sentences.

The first column is a positive control so we can be certain all four samples contained good quality mRNA and therefore blank lanes for the Olr genes indicates no detectable transcription. The sciatic nerve and Schwann cells both transcribe these 10 olfactory receptor genes while the dorsal root ganglion and fibroblasts do not (at least to the detectable limits of RT-PCR).

f) Speculate what the therapeutic implications might be for these data, assuming these proteins maintain their traditional molecular function. Limit your answer to no more than two sentences. If these Olr genes are translated, then we would expect them to be located in the plasma membranes of neuron and Schwann cells (which form myelin covering of neurons). Therefore it might be possible to determine what odorants bind to these receptors and use them as potential therapeutic agents to stimulate regeneration or repair.